Brokerages Anticipate Teva Pharmaceutical Industries Ltd (TEVA) Will Post Quarterly Sales of $4.53 Billion

Share on StockTwits

Equities analysts predict that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will report sales of $4.53 billion for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for Teva Pharmaceutical Industries’ earnings. The lowest sales estimate is $4.41 billion and the highest is $4.76 billion. Teva Pharmaceutical Industries reported sales of $5.46 billion in the same quarter last year, which would suggest a negative year-over-year growth rate of 17%. The company is scheduled to report its next earnings report on Thursday, February 14th.

According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full year sales of $18.85 billion for the current fiscal year, with estimates ranging from $18.71 billion to $19.05 billion. For the next fiscal year, analysts forecast that the company will report sales of $17.89 billion, with estimates ranging from $17.22 billion to $18.15 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Thursday, November 1st. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.53 by $0.11. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. The company had revenue of $4.53 billion during the quarter, compared to analyst estimates of $4.54 billion. During the same period last year, the firm posted $1.00 EPS. Teva Pharmaceutical Industries’s revenue for the quarter was down 19.4% compared to the same quarter last year.

A number of equities analysts have issued reports on TEVA shares. Cantor Fitzgerald set a $25.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Friday, July 13th. Royal Bank of Canada reaffirmed a “hold” rating and set a $19.00 target price on shares of Teva Pharmaceutical Industries in a report on Tuesday, July 31st. Wells Fargo & Co set a $23.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Thursday, August 2nd. Mizuho reaffirmed a “buy” rating and set a $27.00 target price on shares of Teva Pharmaceutical Industries in a report on Thursday, August 2nd. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, August 2nd. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $21.58.

In related news, insider Deborah A. Griffin sold 2,376 shares of the business’s stock in a transaction on Tuesday, September 18th. The shares were sold at an average price of $23.71, for a total value of $56,334.96. Following the completion of the sale, the insider now owns 2,376 shares of the company’s stock, valued at approximately $56,334.96. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Richard Daniell sold 2,488 shares of the business’s stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $23.69, for a total transaction of $58,940.72. Following the completion of the sale, the vice president now directly owns 2,488 shares of the company’s stock, valued at approximately $58,940.72. The disclosure for this sale can be found here. In the last three months, insiders sold 6,531 shares of company stock valued at $152,749. 0.43% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of TEVA. PointState Capital LP acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth $161,826,000. FMR LLC boosted its stake in Teva Pharmaceutical Industries by 19.1% during the 3rd quarter. FMR LLC now owns 24,481,936 shares of the company’s stock worth $527,341,000 after purchasing an additional 3,921,785 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth $90,746,000. Renaissance Technologies LLC boosted its stake in Teva Pharmaceutical Industries by 348.1% during the 2nd quarter. Renaissance Technologies LLC now owns 4,036,863 shares of the company’s stock worth $98,177,000 after purchasing an additional 3,135,900 shares during the last quarter. Finally, Beck Mack & Oliver LLC acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth $64,484,000. 65.10% of the stock is owned by institutional investors.

TEVA traded down $0.39 during trading on Monday, reaching $23.45. 6,637,061 shares of the company’s stock were exchanged, compared to its average volume of 10,918,274. Teva Pharmaceutical Industries has a 1 year low of $11.44 and a 1 year high of $25.96. The company has a current ratio of 0.94, a quick ratio of 0.61 and a debt-to-equity ratio of 1.75. The firm has a market capitalization of $24.13 billion, a PE ratio of 7.39, a P/E/G ratio of 7.28 and a beta of 0.77.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Read More: What is dollar cost averaging (DCA)?

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.